Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 5.


Coen, Oliver, Corrie, Pippa, Marshall, Helen, Plummer, Ruth, Ottensmeier, Christian ORCID: 0000-0003-3619-1657, Hook, Jane, Bell, Sue, Sagoo, Gurdeep S, Meads, David, Bestall, Janine
et al (show 10 more authors) (2021) The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC CANCER, 21 (1). 761-.


Fennell, Dean A, Ewings, Sean, Ottensmeier, Christian ORCID: 0000-0003-3619-1657, Califano, Raffaele, Hanna, Gerard G, Hill, Kayleigh, Danson, Sarah, Steele, Nicola, Nye, Mavis, Johnson, Lucy
et al (show 11 more authors) (2021) Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. LANCET ONCOLOGY, 22 (11). pp. 1530-1540.


Arriola, Edurne, Wheater, Matthew, Galea, Ian, Cross, Nadia, Maishman, Tom, Hamid, Debbie, Stanton, Louise, Cave, Judith, Geldart, Tom, Mulatero, Clive
et al (show 6 more authors) (2016) Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. JOURNAL OF THORACIC ONCOLOGY, 11 (9). pp. 1511-1521.


Kristeleit, Rebecca ORCID: 0000-0003-3825-1326, Plummer, Ruth, Jones, Robert ORCID: 0000-0001-5608-001X, Carter, Louise, Blagden, Sarah ORCID: 0000-0001-8783-3491, Sarker, Debashis ORCID: 0000-0003-4814-8429, Arkenau, Tobias, Evans, Thomas R Jeffry, Danson, Sarah, Symeonides, Stefan N ORCID: 0000-0002-9892-9314
et al (show 4 more authors) (2023) A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. British journal of cancer, 129 (1). pp. 38-45.


Danson, Sarah, Plummer, Ruth, Ottensmeier, Christian ORCID: 0000-0003-3619-1657, Hook, Jane, Marshall, Helen, Sagoo, Gurdeep, Meads, David, Bestall, Janine, Velikova, Galina, Gallagher, Ferdia
et al (show 6 more authors) (2019) A randomised phase III multicentre trial to evaluate the duration of anti-PD1 monoclonal antibody monotherapy in patients with metastatic melanoma (DANTE) - Stage 1 Results. .

This list was generated on Sun Dec 24 05:13:16 2023 GMT.